 |
|
Treatment outcomes highlight dangers of extensively drug-resistant tuberculosis
August 07, 2008In a retrospective study of 174 tuberculosis patients treated at National Jewish Health (formerly National Jewish Medical and Research Center), patients with extensively-drug-resistant tuberculosis (XDR-TB) were almost eight times as likely to die as patients with multi-drug resistant tuberculosis (MDR-TB). National Jewish Health is a national referral center for the treatment of drug-resistant tuberculosis, and its physicians are recognized worldwide for their expertise in the treatment of drug-resistant tuberculosis.
The study, published in the August 17, 2008, issue of The New England Journal of Medicine, highlights the need for optimal management of multi-drug resistant cases to prevent the progression to XDR-TB, associated with poorer outcomes, including greater risk of death from tuberculosis.
"Over the years, we have become quite proficient at treating multi-drug resistant tuberculosis with initial treatment success rates greater than 90 percent in recent years," said lead author Michael Iseman, MD, Professor of Medicine at National Jewish. "Extensively drug-resistant cases, however, are much more difficult to treat and we still lose more of these patients than we save.
Drug-resistance has become a major problem in the treatment of tuberculosis, making the most effective and best tolerated medications ineffective for millions of patients around the world. Drug resistance arises when inadequate treatment kills most, but not all, of the tuberculosis organisms in a patient; the remaining organisms have often mutated to become resistant to various medications. While multi-drug resistance has been known for many years, XDR-TB was first recognized in March 2006.
MDR-TB is now defined as resistance to at least two first-line drugs, isoniazid and rifampin. XDR-TB is resistant to rifampin, isoniazid, a fluoroquinolone and a second-line injectable drug.
National Jewish researchers previously reported an overall long-term success rate between 1984 and 1998 of 75 percent for treatment of MDR-TB. Subsequent analysis revealed initial treatment success rates of greater than 90 percent in the years 1994-1998.
The researchers decided to revisit their data after the recognition of XDR-TB. Of 174 MDR-TB patients who had undergone sufficient drug-susceptibility testing, 10 were classified as XDR-TB, and 164 as MDR-TB. Among multi-drug resistant cases, 14 died from tuberculosis or surgery to treat the disease, and 22 died from other causes. Among the 10 XDR-TB patients, five died, all of TB or surgery to treat it.
Statistical analysis showed that MDR-TB patients were 23.4 times as likely as XDR-TB patients to have initial treatment success, defined as no TB organisms cultured from repeated sputum samples over a three month period during active treatment. MDR-TB patients were 21.1 times as likely as XDR-TB patients to have long-term success: completion of therapy and no evidence of TB organisms in their sputum or lungs for the duration of follow-up, which lasted at least five years and as long as 15 years.
XDR-TB patients were 7.9 times as likely as MDR-TB patients to die from tuberculosis or surgery to treat it, and 2.5 times as likely to die from all causes during follow up.
"These data underscore the critical important of optimal management of cases of multidrug-resistant tuberculosis, lest they develop into extensively drug-resistant tuberculosis," wrote the authors.
National Jewish Medical and Research Center
Drug-resistance has become a major problem in the treatment of tuberculosis, making the most effective and best tolerated medications ineffective for millions of patients around the world. Drug resistance arises when inadequate treatment kills most, but not all, of the tuberculosis organisms in a patient; the remaining organisms have often mutated to become resistant to various medications. While multi-drug resistance has been known for many years, XDR-TB was first recognized in March 2006.
MDR-TB is now defined as resistance to at least two first-line drugs, isoniazid and rifampin. XDR-TB is resistant to rifampin, isoniazid, a fluoroquinolone and a second-line injectable drug.
National Jewish researchers previously reported an overall long-term success rate between 1984 and 1998 of 75 percent for treatment of MDR-TB. Subsequent analysis revealed initial treatment success rates of greater than 90 percent in the years 1994-1998.
The researchers decided to revisit their data after the recognition of XDR-TB. Of 174 MDR-TB patients who had undergone sufficient drug-susceptibility testing, 10 were classified as XDR-TB, and 164 as MDR-TB. Among multi-drug resistant cases, 14 died from tuberculosis or surgery to treat the disease, and 22 died from other causes. Among the 10 XDR-TB patients, five died, all of TB or surgery to treat it.
Statistical analysis showed that MDR-TB patients were 23.4 times as likely as XDR-TB patients to have initial treatment success, defined as no TB organisms cultured from repeated sputum samples over a three month period during active treatment. MDR-TB patients were 21.1 times as likely as XDR-TB patients to have long-term success: completion of therapy and no evidence of TB organisms in their sputum or lungs for the duration of follow-up, which lasted at least five years and as long as 15 years.
XDR-TB patients were 7.9 times as likely as MDR-TB patients to die from tuberculosis or surgery to treat it, and 2.5 times as likely to die from all causes during follow up.
"These data underscore the critical important of optimal management of cases of multidrug-resistant tuberculosis, lest they develop into extensively drug-resistant tuberculosis," wrote the authors.
National Jewish Medical and Research Center
Tuberculosis Current Events and Tuberculosis News RSSStopping germs from ganging up on humans
Keeping germs from cooperating can delay the evolution of drug resistance more effectively than killing germs one by one with traditional drugs such as antibiotics, according to new research from The University of Arizona in Tucson.
First trachea transplant without immunosuppression
After 4 years of going from consultation to consultation, Claudia Castillo finally found a solution to her respiratory problems. The young Colombian woman suffered from a cough that took a long time to be diagnosed as tuberculosis.
Proteomics Study Yields Clues As To How Tuberculosis Might Be Thwarting The Immune System
A link between the immune system and the self-cleaning system by which biological cells rid themselves of obsolete or toxic parts may one day yield new weapons in the fight against tuberculosis and other deadly infectious diseases.
XDR-TB: Deadlier and more mysterious than ever
New research has found that XDR-TB is increasingly common and more deadly than previously known. Extensively drug-resistant tuberculosis (XDR-TB) is a growing public health threat that is only just beginning to be understood by medical and public health officials.
Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment
New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection.
Parasites that live inside cells use loophole to thwart immune system
St. Jude Children's Research Hospital scientists have discovered a mechanism by which intracellular pathogens can shut down one of the body's key chemical weapons against them: nitric oxide.
Persistent bacterial infection exploits killing machinery of immune cells
A new study reveals an important and newly discovered pathway used by disease-causing bacteria to evade the host immune system and survive and grow within the very cells meant to destroy them. This discovery may lead to new treatments and vaccines for tuberculosis (TB) and certain other chronic bacterial and parasitic infections.
Health Care Barriers for Undocumented Immigrants: Raising Tuberculosis Risk?
A new study raises the question, do barriers to health care for undocumented immigrants increase the public health risk of tuberculosis? The study, published in the November 15, 2008 issue of Clinical Infectious Diseases and now available online, suggests that undocumented immigrants with tuberculosis have symptoms longer before seeking care than documented immigrants or U.S.-born patients, resulting in more severe symptoms and more opportunities for transmission.
UCLA develops safer, more effective TB vaccine for HIV-positive people
UCLA scientists engineered a new tuberculosis (TB) vaccine specifically designed for HIV-positive people that was shown to be safer and more potent than the current TB vaccine in preclinical trials.
New TB test reveals patients at risk, says study
A recently introduced blood test can reveal which patients may develop active tuberculosis (TB) much more precisely than the 100-year old TB skin test, according to a new study published today in the journal Annals of Internal Medicine.
More Tuberculosis Current Events and Tuberculosis News Articles
 | Timebomb : The Global Epidemic of Multi-Drug Resistant Tuberculosis by Lee Reichman, Janice Hopkins Tanne "A chilling account of... the global resurgence of this disease..."--The New York Times "Tuberculosis--a nineteenth century disease--has come back with a vengeance... Timebomb is the extraordinary story of courage and cowardice in confronting the global TB epidemic."--Donna E. Shalala, former Secretary of Health and Human Services, President of the University of... |
 | The Forgotten Plague: How the Battle Against Tuberculosis Was Won - And Lost by Frank Ryan Tuberculosis has claimed more than a billion lives worldwide. In this acclaimed book, Dr. Frank Ryan tells the remarkable story of the dedicated doctors, chemists, and bacteriologists who halted the course of this ferocious disease--until the "old enemy" found in AIDS a deadly ally to form a drug-resistant synergy. 8 pages of... |
 | Tuberculosis (TUBERCULOSIS ( ROM)) This comprehensive clinical reference is edited by experts from the NYU-Bellevue Chest Service, which through its influence in tuberculosis care and education has been an integral part of the formation of the entire specialty of pulmonary medicine. The book draws on this extensive experience to present an authoritative account of the history, epidemiology, microbiology, immunology, clinical... |
 | Tuberculosis (Twenty-First Century Medical Library) by Diane Yancey One of the deadliest diseases healthcare workers fight today, tuberculosis (often called TB) infects the lungs of one-third of the world's population and kills about 2 million people a year. While scientific breakthroughs brought this bacterial disease under control during the 1960s to the 1980s, it was never completely eliminated. In the early 1990s, TB came back as a serious global threat. Not... |
 | Clinical Tuberculosis (A Hodder Arnold Publication) by Peter D Davies, Peeter Barnes, Stephen B Gordon Clinical Tuberculosis remains an indispensable resource for respiratory physicians, infectious disease specialists, public health workers and other individuals involved in the management and control of tuberculosis worldwide. This established reference is a comprehensive accoutn of tuberculosis, providing up-to-date and authoritative information on all aspects of the disease. It gives practical... |
 | Diagnostics for tuberculosis: Global demand and market potential by World Health Organization's Special Programme for Tropical Diseases Research (TDR) In this report the World Health Organization's Special Programme for Tropical Diseases Research (TDR), in collaboration with the Foundation for Innovative New Diagnostics (FIND), has compiled existing epidemiological data and generated a wealth of new data on the availability of TB laboratory services, variations in physician diagnostic practices, workloads of national laboratory networks, and... |
| The Modern Epidemic: A History of Tuberculosis in Japan (Harvard East Asian Monographs) by William Johnston Through a historical and comparative analysis of modern Japan's epidemic of tuberculosis, William Johnston illuminates a major but relatively unexamined facet of Japanese social and cultural history. He utilizes a broad range of sources, including medical journals and monographs, archaeological evidence, literary works, ethnographic data, and legal and government documents to reveal how this and... | |
| White Death: A History of Tuberculosis by Thomas Dormandy The victims of tuberculosis (TB; usually known as consumption) included not only Keats, the Brontes, Chopin & Chekhov but members of almost every family. It was a killer on a huge scale. This highly praised book provides a history of tuberculosis as a whole. Thomas Dormandy's account of the search for a cure is complemented by a description of the disease's complex natural history; & by portraits... | |
 | Mycobacterium Tuberculosis Protocols (Methods in Molecular Medicine) (Methods in Molecular Medicine) Leading investigators with extensive practical knowledge and experience describe their best methods for studying the tuberculosis pathogen. Packed with step-by-step instructions to ensure successful results, these methods range from basic handling techniques to the application of functional genomics. Highlights include methods for the basic safety and culture of M. tuberculosis, fractionation of... |
 | Handbook of Tuberculosis Tuberculosis (TB), a deadly airborne disease caused by the bacterium Mycobacterium tuberculosis, takes the lives of almost 2 million people each year and is considered to be the most common infectious disease in the world. However, thanks to the efforts of researchers such as the volumes’ lead editor, Dr. Stefan H. E. Kaufmann, there have been several recent advances in fighting the disease. ... |
| © 2008 BrightSurf.com |